Navigation Links
Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
Date:4/27/2012

ction. The product pipeline includes new uses for previously approved drugs and new molecular entities ("NMEs"). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. For more information about Ampio, please visit our website, www.ampiopharma.com.

Forward-Looking Statements
Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, successful commercialization and marketing of Zertane™ and the combination drug in Korea, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Contact: Investor Relations, Ampio Pharmaceuticals, Inc., 720-437-6500


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ampio Strengthens Patent Protection for Lead Drug Ampion™
2. Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule
3. Champions Oncology Reports Fiscal 2012 Third Quarter Financial Results
4. Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
5. Ampio Pharmaceuticals Schedules 2012 Outlook Webcast
6. Executive Changes at Ampio
7. Ampio Pharmaceuticals Schedules Webcast to Update Shareholders
8. Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million
9. Ampio Responds to Recent Publications by Anonymous Short Sellers
10. Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
11. FDA Advisory Panel Recommends Against Approval of Champion® Heart Failure Management System for Patients With Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... , Sept. 4, 2015  PTC Therapeutics, ... announce five recipients of its first-ever global awards ... Vision and Empowerment), designed to aid nonprofit organizations ... dystrophy (DMD) community. The announcement is made as ... World Duchenne Awareness Day on Monday, September 7, ...
(Date:9/4/2015)... , September 4, 2015 ... ), a clinical-stage pharmaceutical company focused on the development ... Company will participate in the upcoming Rodman & Renshaw ... September 8-10, 2015 in New York City ... Oramed, will present a corporate overview on September 9, ...
(Date:9/4/2015)... , September 4, 2015 Future ... Allergic Rhinitis drugs - new ... Where is the market for allergic rhinitis drugs ... Visiongain ,s new report shows you potential revenues ... prospects. Our 326 page report provides 273 ...
Breaking Medicine Technology:PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 2PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 3PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 4Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7
... Globus Medical, Inc., the largest,privately held spinal ... in motion preservation technology, today announced the completion ... study. The,SECURE(R)-C device is designed to mimic the ... pain and restore function as an alternative to ...
... Siemens Healthcare and,Laboratory Corporation of America(R) Holdings ... non-exclusive agreement to discuss future,possibilities to co-develop ... of,companion diagnostics, metabolic syndrome, oncology and diabetes. ... developing new tests that,could make the biggest ...
Cached Medicine Technology:Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 3Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 4
(Date:9/4/2015)... Los Angeles, CA (PRWEB) , ... September 04, 2015 , ... ... many of the elderly Americans currently being cared for in nursing homes and assisted ... Specifically, the author discussed a personal story in which her father was at one ...
(Date:9/4/2015)... , ... September 04, 2015 , ... According to an ... Journal of the American Dental Association presented data showing that it is safe for ... group of pregnant women that had undergone local anesthesia with a group that hadn’t, ...
(Date:9/4/2015)... Aliso Viejo, CA (PRWEB) , ... September 04, 2015 , ... ... a click of a mouse all within Final Cut Pro X. With TransCel users ... finish. Adjust the frame width, background color, speed method, frame color, inner color, text, ...
(Date:9/4/2015)... California (PRWEB) , ... September 04, 2015 , ... The ... behalf of Tanya De La Paz. , Schmidt National Law Group, a leading ... Northern District of California against Bayer Corp., Bayer Essure, Inc., and other Bayer affiliates ...
(Date:9/4/2015)... , ... September 04, 2015 , ... IVF New England, ... a New Hampshire fertility "ManchVegas Happy Hour" in Manchester for women who wish to ... 2015 at XO on Elm restaurant and lounge, 827 Elm Street, Manchester, NH from ...
Breaking Medicine News(10 mins):Health News:Op-Ed about Insufficient Care for Elderly Patients Highlights the Advantages of Quality, At-Home Care, says Dr. Michael Farzam 2Health News:Op-Ed about Insufficient Care for Elderly Patients Highlights the Advantages of Quality, At-Home Care, says Dr. Michael Farzam 3Health News:Recent Study on Dental Care During Pregnancy Demonstrates How Preventative Dental Care Really is for Everyone, Says Medical Center Dental Care 2Health News:Pixel Film Studios Releases TransCel, a New FCPX Transition 2Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:IVF New England to Host ManchVegas New Hampshire Fertility Happy Hour on October 15, 2015 in Manchester for Women Who Wish to Learn More About Fertility and Egg Freezing 2
... DALLAS, Feb. 24 Hospitals need a "civility ... Beryl Institute, hospitals need to go,beyond traditional customer ... relate to others. The white paper, "Character Counts:,Integrating ... Chuck Lauer,former publisher of Modern Healthcare and frequent ...
... Feb. 24 Service Corporation International (NYSE: SCI ) announced ... fourth quarter 2008 on Wednesday, February 25, 2009, after the market closes. ... February 26, 2009. Details of the conference call are as follows: ... Service Corporation International Fourth Quarter 2008, Earnings Conference ...
... Backdrop of JAMA Report on Post-Diagnosis Joblessness, Legal and ... -DALLAS, Feb. 24 Cancer and Careers, along with ... Beyond Breast Cancer (LBBC), the Young Survival Coalition (YSC) ... their educational workshop, " Managing Cancer and Careers ," ...
... Swann Appear On ,Fox & Friends, ,NY1, ,TheStreet.com ... Calif., Feb. 24 Transdel Pharmaceuticals, Inc. (OTC ... pharmaceutical company focused on developing and commercializing non-invasive, ... with Board Member Lynn Swann on "Fox & ...
... 9 are first target indicationsHOUSTON, Feb. 24 Stem ... has additional application in the production of biosimilar and ... proteins are liver products and comprise a multibillion dollar ... of SCLL. "Albumin, the clotting factors and alpha-1-antitrypsin ...
... VANCOUVER, Feb. 24 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: ... of Appeals for the First Circuit (the "Court of Appeals") ... Banc ("QLT Petition") of the January 12, 2009 Court of ... 2009. The January 12, 2009 Court of Appeals decision upheld ...
Cached Medicine News:Health News:Where's the Civility in Healthcare? New White Paper from The Beryl Institute Explores Why Character Counts in Healthcare 2Health News:Service Corporation International Announces Schedule for Its Fourth Quarter 2008 Earnings Release and Conference Call 2Health News:Young Women Learn to Strike a Balance Between Breast Cancer and Careers 2Health News:Young Women Learn to Strike a Balance Between Breast Cancer and Careers 3Health News:Young Women Learn to Strike a Balance Between Breast Cancer and Careers 4Health News:Young Women Learn to Strike a Balance Between Breast Cancer and Careers 5Health News:Transdel Pharmaceuticals, Inc. Featured on National Broadcast Television 2Health News:Transdel Pharmaceuticals, Inc. Featured on National Broadcast Television 3Health News:Stem Cell Innovations' C3A Human Liver Cell Line is Capable of Producing Biosimilar Serum Proteins for Follow-On Biologics 2Health News:Stem Cell Innovations' C3A Human Liver Cell Line is Capable of Producing Biosimilar Serum Proteins for Follow-On Biologics 3Health News:QLT petition for rehearing of Massachusetts Eye and Ear Infirmary litigation is denied 2Health News:QLT petition for rehearing of Massachusetts Eye and Ear Infirmary litigation is denied 3
... feature a low implant profile, 0.84mm, for ... single-quadrant insertion is technically simpler and allows ... be installed with less trauma than multiple ... Baerveldt implant were designed to minimize bleb ...
... is lightweight enough to shuttle easily between ... Designed with a goldmann standard 30 cm ... with 79 locations (including 30-2, 24-2, and ... different suprathresholds out to 30. Easyfield ...
The most versatile 90 full field perimeter for static- and kinetic perimetry. It incorporates standard White-on-White and Blue-on-Yellow static perimetry. Octopus 101 covers all the needs in clinics ...
... Designed around the patented Interzeag ... 301 sets the trend in ... Ideal for routine screening and ... performance, accuracy and quality of ...
Medicine Products: